Paper Details

  1. Home
  2. Paper Details

Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials.

Author: ChenChangzheng, GommollCarl, GreenbergWilliam M, SambunarisAngelo

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Levomilnacipran extended-release (ER) was more effective than placebo in improving functional impairment in patients with major depressive disorder (MDD). The improvement in functional outcomes was observed across various subgroups, including both sexes and different age groups, regardless of baseline depression severity and functional impairment levels.
Paper Details　
Original Abstract of the Article :
Major depressive disorder (MDD) is characterized by increased rates of impaired function and disability. During antidepressant treatment, functional improvement often lags behind symptomatic resolution, and residual impairment is associated with an increased risk for relapse. When evaluating MDD tre...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4047314/

データ提供：米国国立医学図書館（NLM）

Efficacy of Levomilnacipran Extended-Release in Improving Functional Impairment Associated with Major Depressive Disorder

Major depressive disorder (MDD) is a pervasive mental health condition that can significantly impact daily life. It's like being lost in a desert of despair, struggling to find your way out. This study investigates the effectiveness of levomilnacipran extended-release, a medication for MDD, in improving functional impairment, a common consequence of this disorder.

Levomilnacipran Extended-Release: A Potential Oasis of Relief

The study found that levomilnacipran extended-release significantly improved functional impairment in patients with MDD, helping them navigate the desert of their condition and regain a sense of control over their lives. It's like finding a hidden spring in the desert, providing a source of renewal and strength.

Hope for Better Functioning

This research offers valuable insights into the treatment of MDD. By focusing on both symptoms and functional impairment, we can help individuals achieve a more comprehensive recovery, enabling them to live more fulfilling lives.

Dr.Camel's Conclusion

This study offers a glimmer of hope in the vast desert of depression, showcasing the potential of levomilnacipran extended-release to improve functional impairment and empower individuals to reclaim their lives. The study highlights the importance of a holistic approach to mental health treatment, addressing both symptoms and functional challenges.

Date :
  1. Date Completed 2015-01-24
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

24667487

DOI: Digital Object Identifier

PMC4047314

Related Literature

Article Analysis
・Effects of levomilnacipran
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.